fashion -WSS

fashion

author：focus 2025-09-27 16:46:59 - browse：7482

Exterior photo of UnitedHealth Group building — UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

There’s now a two-party showdown for one of the largest home health companies in the country.

UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Galapagos to make CAR

WSS

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

STAT reporters are Pulitzer Prize finalists for investigative reporting

Publishing genetic code of viruses could cause disaster

Ohio still needs to do more to protect the right to abortion

Healthy food access boosts outcomes in two studies

A letter from the executive editor: STAT UnitedHealth investigation

hotspot

fashion

focus

How one medical school became remarkably diverse

WuXi Biologics execs register to lobby as Congress comes for the company

Affirmative action in medical school literally saved lives

CVS is willing to dump 10% of its Medicare Advantage members

How to save PrEP access — and even expand it

Healthy food access boosts outcomes in two studies

Bright Health sells Medicare Advantage business to Molina

NIH chief: government has fallen behind pharma on clinical trials

New air purifier tech could be key to improving indoor air quality

FDA reorg will put new emphasis on investigations, sources say

focus

Weight loss drugs should be covered by insurers, AMA says

Readout Newsletter: Zepbound, Valneva's vaccine, and more

How state and local governments are sidelining science

CVS is willing to dump 10% of its Medicare Advantage members

How state and local governments are sidelining science

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

hotspot

hotspot

hotspot

hotspot